x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:14:47

Press Release Updates

OncoPharm ·

2023/10/05

Trying to make sense of the limited information put out via Press Release the last 2 weeks for mobocertinib, pembrolizumab + enfortumab vedotin, nivolumab, and more.

en

00:19:14

Imatinib [Re-release]

OncoPharm ·

2023/09/28

From the Foundations of OncoPharm archives - the history and groundbreaking STI 571 (imatinib).

en

00:11:20

Carboplatin Paclitaxel in Ovarian Cancer

OncoPharm ·

2023/09/21

It's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago. carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542

en

00:11:16

HER3-DXd & Motixafortide

OncoPharm ·

2023/09/14

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).

en

00:13:30

RECISTance Is Futile

OncoPharm ·

2023/09/07

You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.

en

00:19:33

DPYD Variant Dosing & ICIs In Pancreatic Cancer

OncoPharm ·

2023/08/31

Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651 Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102

en

00:15:17

Nab-Paclitaxel

OncoPharm ·

2023/08/24

A Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.

en

00:14:25

Niraparib + Abiraterone, Elranatamab, & Melphalan...

OncoPharm ·

2023/08/17

A combination product is now available of niraparib + abiraterone for use in mCRPC. Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.

en

00:15:05

Talquetamab & STOP-CA

OncoPharm ·

2023/08/10

Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity. STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988

en

00:14:29

Ruby Trial & Quizartinib Toxicity

OncoPharm ·

2023/08/03

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients. Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.

en

00:13:35

BCOP Study Tips

OncoPharm ·

2023/07/27

By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.

en

00:13:36

Chemotherapy Sequencing In Colorectal Cancer

OncoPharm ·

2023/07/20

A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI. Some interesting dosing to discuss in this study. Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692

en

00:39:04

Phase 1 Clinical Trials In Oncology with Dr. Donald...

OncoPharm ·

2023/07/13

We welcome Dr. Donald Harvey to the podcast to discuss Phase 1 clinical trials in oncology. Topics include goals of Phase 1 trials, how these early studies are conducted, how doses are determined, and some limitations of current practices.

en

00:29:09

Investigational Drug Services In Oncology with Dr....

OncoPharm ·

2023/07/06

We welcome Jacqueline (Jackie) Saunders to the podcast to talk about investigational drug services (IDS) in oncology and how pharmacists manage the storage, preparation, & delivery of experimental drugs.

en

00:15:26

NADIM II & Favorable Risk RCC

OncoPharm ·

2023/06/29

This episode... More evidence to support the use of neoadjuvant ICI/chemo in stage III NSCLC to obtain pCR published this week with NADIM II. Time to rethink giving ICI/TKI combination therapy to favorable-risk metastatic RCC patients? (Finally, I'm not the only one saying this anymore.) NADIM II: https://www.nejm.org/doi/full/10.1056/NEJMoa2215530 FDA Pooled Analysis Favorable Risk metastatic RCC: https://doi.org/10.1016/j.eururo.2023.05.030

en

00:12:59

Glofitamab & TALAPRO - 2

OncoPharm ·

2023/06/22

This week's Pod looks at the 2nd CD20-CD3 bispecific T-Cell engager approved this year (or at all), glofitamab, and the TALAPRO-2 study of combining talazoparib to enzalutaimide. TALAPRO-2: https://doi.org/10.1016/S0140-6736(23)01055-3

en

00:27:37

ASCO '23 Entrees

OncoPharm ·

2023/06/15

We highlight notable data from this month's ASCO annual meeting. 1. SONIA: sequence (1st or 2nd-line) CKD 4/6i in MBC 2. ADAURA OS results and low rate of osimertinib use in control arm 3. Keynote 671: perioperative pembrolizumab in NSCLC 4. PROSPECT: Can radiation therapy be omitted in locally advanced rectal cancer? 5. Nivo-AVD vs. Bv-AVD in stage III Hodgkin's (ages 12+) 6. ZUMA-7: 2nd line Axl-Cel OS benefit in aggressive NHL (early relapse/refractory disease) 7. CARTITUDE-4: Cilta-Cel earlier

en

00:11:56

ASCO '23 Appetizers

OncoPharm ·

2023/06/08

ASCO '23 Appetizers by John Bossaer

en

00:17:09

PROpel and Cilostazol to Prevent Paclitaxel Neuropathy

OncoPharm ·

2023/06/01

Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population. Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol? PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043 Cilostazol RCT: https://doi.org/10.1002/phar.2830 Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514

en

00:15:32

Epcoritamab

OncoPharm ·

2023/05/25

We discuss the newly approved CD20-CD3 T-cell engager for subcutaneous (SC) administration to treat DLBLC after 2 or more lines of therapy.

en

422 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter